Last reviewed · How we verify
NCT03348813
HIV/STI Prevention Among Black Adolescents With Mental Illnesses (Project GOLD)
NA trial testing HIV/STI Prevention Intervention in HIV in 108 participants. Completed in 31 December 2016.
22 December 2016
Quick facts
| Lead sponsor | University of Pennsylvania |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 108 |
| Start date | 1 August 2014 |
| Primary completion | 22 December 2016 |
| Estimated completion | 31 December 2016 |
| Sites | 1 location across United States |
Drugs / interventions tested
- HIV/STI Prevention Intervention
- General Health Control Intervention
Conditions studied
- HIV — all drugs for HIV →
- STI — all drugs for STI →
- Emotional Disturbances — all drugs for Emotional Disturbances →
- Mental Disorder — all drugs for Mental Disorder →
Sponsor
University of Pennsylvania
Who can join
Adults 14 to 17, any sex, with HIV or STI. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Despite advances in HIV/sexually transmitted infection (STI) prevention, Black youth account for the largest number of new HIV infections among heterosexual youth. Having a mental illness contributes to HIV/STI risk among heterosexually active Black youth, as some use sex as a means to manage psychological distress, regulate emotions and receive validation or acceptance. Current intervention models focus on cognitive-behavioral strategies to reduce risk among adolescents; however, these approaches in isolation do not address the psychopathology that further potentiates risk behaviors among adolescents with mental illnesses. This randomized controlled trial evaluated the effects of "Project GOLD", a theoretically-driven, gender and culturally relevant, developmentally and psychologically appropriate HIV/STI risk reduction intervention on the sexual behaviors of Black male and female adolescents in Philadelphia (aged 14-17). In addition to evidence-based HIV/STI preventions strategies (e.g., role playing), Project GOLD includes unique emotion regulation content to address the relationship between psychological distress and HIV/STI risk behaviors. The research team approached and screened 704 adolescents. Eighty-two participated in the elicitation research activities (e.g., focus groups, intervention dress rehearsal). Another 173 underwent a structured demographic and mental health diagnostic interview to determine RCT eligibility. Project GOLD was then tested with 108 Black youth in comparison to a general health promotion control condition (intervention n = 52; control n = 56). Youth who were not in psychiatric treatment were also included, as the investigators hypothesized that they would also benefit from the targeted psychoeducational content; post-hoc analyses examined differences in the intervention effects based on whether or not youth were in psychiatric treatment. The intervention had high feasibility and acceptability. These findings underscore the need to encourage HIV/STI testing and risk reduction efforts among Black youth, including those with mental illnesses.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Vital Voices: HIV Prevention and Care Interventions Developed for Disproportionately Affected Communities by Historically Underrepresented, Early-Career Scientists.
Sutton MY, Martinez O, Brawner BM, Prado G, et al · · 2021 · cited 13× · PMID 33128188 · DOI 10.1007/s40615-020-00908-2 -
Project GOLD: A pilot randomized controlled trial of a novel psychoeducational HIV/STI prevention intervention for heterosexually-active black youth.
Brawner BM, Jemmott LS, Wingood G, Lozano AJ, et al · · 2019 · cited 5× · PMID 30730043 · DOI 10.1002/nur.21930 -
Results from Project GOLD: A pilot randomized controlled trial of a psychoeducational HIV/STI prevention intervention for black youth.
Brawner BM, Jemmott LS, Hanlon AL, Lozano AJ, et al · · 2021 · cited 3× · PMID 33550841 · DOI 10.1080/09540121.2021.1874273
Verify or expand the search:
- PubMed search for NCT03348813
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HIV
Currently open trials in the same condition.
- NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
- NCT07221214 — GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV · Phase 2 · recruiting
- NCT07226128 — The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV · NA · recruiting
- NCT07390474 — Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA i · Phase 1 · recruiting
- NCT07390955 — A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1 · Phase 1 · recruiting
Other University of Pennsylvania trials
Trials by the same sponsor.
- NCT06081153 — Mechanistic Clinical Trial of PCSK9 Inhibition for AAA · EARLY_PHASE1 · not yet recruiting
- NCT07415772 — Effect of cTBS on Startle and TMS-evoked BOLD · NA · not yet recruiting
- NCT07489430 — DaxibotulinumtoxinA for Blepharospasm · Phase 2 · not yet recruiting
- NCT07463131 — Negative Income Tax Trial · NA · not yet recruiting
- NCT06645769 — Na-Phenylbutyrate VAscular Trial · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03348813 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Pennsylvania
- Last refreshed: 29 November 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03348813.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing